Clinical Trial Update: A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis [Phase 3]

View source ↗

Summary

A 58-week Phase 3 trial evaluating the safety and efficacy of Ferric Citrate in patients with end-stage renal disease on dialysis for hyperphosphatemia; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• Ferric citrate (ferric citrate)

Snippet

Sponsor: Keryx Biopharmaceuticals | Conditions: Hyperphosphatemia, Kidney Failure | Phase 3 | Status: COMPLETED | Results posted: 2014-12-10